NCT04834128View on ClinicalTrials.gov

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 13, 2021

Primary Completion Date

April 13, 2022

Study Completion Date

April 13, 2022

Conditions
COVID - 19
Interventions
DRUG

TCB008

administration of gamma delta T cells by IV bolus injection

Trial Locations (1)

Unknown

Royal Victoria Infirmary, Newcastle

Sponsors

Lead Sponsor

TC Biopharm
All Listed Sponsors
lead

TC Biopharm

INDUSTRY

NCT04834128 - A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19 | Biotech Hunter | Biotech Hunter